Skip to main content
Bora Lim, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

BoraLimMD

Oncology Houston, TX

Breast Cancer, Hematologic Oncology

Associate Professor Breast Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

Dr. Lim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lim's full profile

Already have an account?

Summary

  • She received her medical degree from Ewha Women's University College of Medicine and has practiced for 20 years. She specializes in breast cancer and hematologic oncology, and translational research, and is experienced in breast cancer, inflammatory breast cancer, metastatic diseases, triple-negative breast cancer, and drug development.

Education & Training

  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Pennsylvania Hospital of the University of Pennsylvania Health System
    Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2011
  • Ewha Women's University College of Medicine
    Ewha Women's University College of MedicineClass of 2004
  • Ewha Womans University
    Ewha Womans UniversityBachelor's, 1998 - 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2014 - 2024
  • PA State Medical License
    PA State Medical License 2007 - 2014
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Multidisciplinary Teacher Award Breast Surgical Oncology Fellows, 2017
  • Best Research Projects for Clinical Fellows PennState College of Medicine, 2014
  • Lou-Dinon Teaching Award University of Pennsylvania Medical Students, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Rates of Immune Cell Infiltration in Patients with Triple-Negative Breast Cancer by Molecular Subtype  
    Wendy A Woodward, Naoto T Ueno, Savitri Krishnamurthy, Bora Lim, PLoS One
  • Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer  
    Michael C Stauder, Anthony Lucci, Wendy A Woodward, Bora Lim, Naoto T Ueno, ScienceDirect
  • International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Con...  
    Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M,..., J Cancer, 1/1/2018
  • Join now to see all

Abstracts/Posters

  • Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer
    Wang W, Matsuda N, Lim B, Krishnamurthy S, Song J, Shen Y, Wu J, Hu J, Woodward WA, Reuben JM, Lucci A, Tripathy D, Valero V, Ueno NT, AACR Annual Meeting, 1/1/2018
  • Identification of molecular therapeutic targets that enhance the antitumor activity of neratinib in breast cancer cells
    Lim B, Lee J, Pearson T, Huey L, Hwang M, Choi K, Avogadri-Connors F, Cutler RE, Jr., Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
  • E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells
    Lee J, Lim B, Choi K, Pearson T, Paradiso L, Myers T, Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
  • Join now to see all

Lectures

  • Novel combination of AR inhibitor and CDK4/6 inhibitor in non-HR positive (Triple Negative) breast cancers 
    Barcelona, Spain - 1/23/2018
  • Clinical Updates, and New Initiatives 
    Houston, TX - 1/20/2018
  • New Upcoming Therapeutics in TNBC 
    Houston, TX - 1/21/2017
  • Join now to see all

Press Mentions

  • Celcuity Using CELSignia Test to Select Breast Cancer Patients for Phase II Trial of Tabrecta, Nerlynx
    Celcuity Using CELSignia Test to Select Breast Cancer Patients for Phase II Trial of Tabrecta, NerlynxMarch 17th, 2021
  • CELC Inks Breast Cancer Trial Collaboration, CANF Soars on Deal with Ewopharma, MRUS on Watch
    CELC Inks Breast Cancer Trial Collaboration, CANF Soars on Deal with Ewopharma, MRUS on WatchMarch 17th, 2021
  • 7 Things to Know About Menopause and Breast Cancer
    7 Things to Know About Menopause and Breast CancerOctober 8th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations